GRIN3A and Alzheimer disease: In the GluN3A KO mouse, we demonstrated that presymptomatic MEM (10–20 mg/day) treatment from 3-month of age for 3 months prevented or attenuated AD brain neuropathology, Aβ production/aggregation, and cognation decline [127, 290].